113-38-2 Usage
Description
17-BETA-ESTRADIOL 3,17-DIPROPIONATE is a synthetic derivative of the naturally occurring hormone estrogen, specifically beta-estradiol. It is characterized by the presence of two propionate groups attached to the 3 and 17 positions of the steroid nucleus. This modification enhances the compound's lipophilicity and stability, allowing for better absorption and longer-lasting effects when administered.
Uses
Used in Pharmaceutical Industry:
17-BETA-ESTRADIOL 3,17-DIPROPIONATE is used as a pharmaceutical compound for the treatment of various conditions related to estrogen deficiency, such as menopausal symptoms, osteoporosis, and hormone replacement therapy. It serves as an estrogen replacement, helping to alleviate symptoms and maintain bone health.
Used in Research Applications:
17-BETA-ESTRADIOL 3,17-DIPROPIONATE is used as a research tool for studying the effects of estrogen on cellular processes and energy metabolism. It is particularly useful in the study of nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis, providing insights into the role of estrogen in cellular metabolism and potential therapeutic applications.
Safety Profile
Confirmed carcinogen
with experimental carcinogenic,
tumorigenic, and teratogenic data. A poison
by intravenous and parenteral routes.
Experimental reproductive effects. A drug for the treatment of menopause. When
heated to decomposition it emits acrid
smoke and irritating fumes. See also
ESTRADIOL.
Check Digit Verification of cas no
The CAS Registry Mumber 113-38-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,1 and 3 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 113-38:
(5*1)+(4*1)+(3*3)+(2*3)+(1*8)=32
32 % 10 = 2
So 113-38-2 is a valid CAS Registry Number.
InChI:InChI=1/C21H28O3/c1-3-20(23)24-19-9-8-18-17-6-4-13-12-14(22)5-7-15(13)16(17)10-11-21(18,19)2/h5,7,12,16-19,22H,3-4,6,8-11H2,1-2H3/t16?,17?,18?,19-,21-/m0/s1
113-38-2Relevant articles and documents
-
Wettstein
, p. 250,252 (1939)
-
Synthesis, anti-oxidant activity, and cytotoxicity of salicyloyl derivatives of estra-1, 3, 5(10)-triene and androst-5-ene
Gasi, Katarina Penov,Djurendic, Evgenija,Dojcinovic-Vujaskovic, Sanja,Gakovic, Andrea,Jovanovic-Santa, Suzana,Kojic, Vesna,Sakac, Marija
scheme or table, p. 284 - 294 (2012/08/28)
Since many estrane and androstane derivatives exhibit cytotoxic, anti-oxidant, or anti-hormone activity, new steroidal derivatives were synthesised from appropriate estrogen or androgen precursors in order to obtain potential therapeutics for the treatment of steroid-dependent diseases. Starting from estradiol (I ), 6-oxo derivatives V and VII were prepared. 17β-Salicyloyl-6-oxo derivatives VI and VIII were synthesised by the reaction of compounds V or VII with methyl salicylate in the presence of sodium. 17β-Salicyloyloxy estradiol IX was prepared from estradiol. Beckmann fragmentation of 16-oxyimino alcohols XII and XIII with methyl salicylate yielded corresponding Dseco derivatives XIV and XV. Simultaneous fragmentation and acylation of compound XII resulted in 3β-salicyloyl-D-seco derivative XVI which was also obtained from compound XIV. Anti-oxidant assays of the newly synthesised compounds V-IX, XIV, and XVI indicated a stronger capacity for hydroxyl radical scavenging, and a weaker capacity for DPPH radical scavenging, compared with the standard anti-oxidants BHA and BHT. Compounds V, XIV, and XVI showed higher or the same activity as BHT. The cytotoxicity of new compounds was evaluated against human breast and prostate carcinoma cells. Compound VI exhibited strong cytotoxicity against MDA-MB-231 cells; compound XIV exhibited strong cytotoxicity against PC-3 cell line, while compound VII moderately inhibited the growth of PC-3 cells.